SARS-CoV-2 mRNA-based vaccines in the Aicardi Goutières Syndrome
Asako Takanohashi(Children's Hospital of Philadelphia), Adeline Vanderver(Children's Hospital of Philadelphia), Russell D’Aiello(Children's Hospital of Philadelphia), Julia Hacker(University of Pennsylvania), Taibeen Khandaker, Devon Cordova(ME Association), Benjamin Davis(University of Pennsylvania), Paulo J.C. Lin(University of British Columbia), Sarah Woidill(Children's Hospital of Philadelphia), Ying K. Tam(Arbutus Biopharma (Canada)), Francesco Gavazzi(Children's Hospital of Philadelphia), Drew Weissman(California University of Pennsylvania), Patrick Winters, Guy Helman(Murdoch Children's Research Institute), Mohamad‐Gabriel Alameh(Children's Hospital of Philadelphia), Justine Shults(Children's Hospital of Philadelphia), Houping Ni(Acuitas Therapeutics (Canada)), Laura Adang(Children's Hospital of Philadelphia)
Cited by 2
Related Papers
mRNA vaccines — a new era in vaccinology
|Nature Reviews Drug Discovery|2018|4.4k
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
|Nature Reviews Drug Discovery|2021|1.5k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k